Aysegül Uner

Hacettepe University, Ankara, Ankara, Turkey

Are you Aysegül Uner?

Claim your profile

Publications (23)56.79 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Tamoxifen has been in the center of management of hormone-sensitive breast cancer. Furthermore, it represents the best example of chemo-prevention: It reduces the incidence of invasive breast cancer. However, it has some side effects, several of them are severe. Oncologists, hematologists, internal medicine specialists and gynecologists must know this agent in detail. Authors report a very rare side effect, thrombocytopenia, and discuss it briefly.
    Medical Oncology 02/2007; 24(4):453-4. · 2.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study, tumour tissue samples of 85 primary breast cancer patients were evaluated for phosphatase and tensin homolog deleted on chromosome ten (PTEN), cyclin D1 and P27/Kip1 expression patterns. The results were correlated with clinicopathological parameters. Loss of PTEN protein expression was present in 32.5% of the cases. Cyclin D1 was overexpressed in 54.2% and P27/Kip1 in 89.3% of the cases. Statistically significant associations were found between PTEN and cyclin D1 expression patterns, and cyclin D1 expression and tumour size.
    Bulletin du cancer 03/2006; 93(2):E21-6. · 0.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 13-year-old boy was referred to the authors' hospital following a right inguinal orchiectomy for a right scrotal mass. Histopathological examination revealed Burkitt lymphoma. The left testis was found to be small with heterogeneous parenchyma by scrotal ultrasound (US) and other systemic investigations were negative for lymphoma involvement. Ultrasound-guided fine-needle aspiration biopsy showed no evidence of involvement in the left testis. Considering stage I Burkitt lymphoma, chemotherapy was started. Following the first course, US findings changed: the volume of the left testis decreased and the parenchyma became homogeneous. The left testis was considered to be involved by lymphoma at initial diagnosis and chemotherapy was intensified. At the end of 5 months of chemotherapy the left testis was again heterogeneous in US. A wedge-biopsy was negative for lymphoma. The patient is under regular follow-up and is in complete remission 19 months after the end of chemotherapy. Primary testicular lymphoma is quite rare in children and experience is limited. Changes in testicular size and parenchyma by US should not necessarily indicate involvement by lymphoma in pubertal boys.
    Pediatric Hematology and Oncology 01/2006; 22(8):705-9. · 0.90 Impact Factor
  • Aysegül Uner, Emin Kansu, James Mc Arthur
    Hematology 11/2005; 10(5):435-6. · 1.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: PTEN is a tumor suppressor gene located on chromosome 10q23 and is amongst the most commonly mutated genes in human cancers. The lipid phosphatase activity of Pten enables it to dephosphorylate PIP3, thereby antagonizing growth factor stimulated PI3-kinase signaling mediated by AKT/PKB. The growth inhibition effect of PTEN has been shown to be mediated by p27 which is one of the important effector molecules downstream of the AKT pathway. Recently the importance of the Pten and AKT pathway in the regulation of the immune system and development of hematological malignancies has been shown. Loss of Pten and p27 expressions were examined immunohistochemically in 45 patients with peripheral T- and NK-cell lymphoma. Partial or complete loss of Pten was detected in 66.7% of the cases of anaplastic large cell lymphoma (ALCL) compared to only 12.5% of all other mature T-/NK-cell lymphomas combined. Loss of p27 was identified in 64.9% of cases, which showed a positive correlation with Pten loss. In this study, we showed that loss of Pten is more frequent in ALCL as compared to other mature T-/NK-cell lymphomas, which strongly correlates with the loss of p27 expression. Our findings provide further evidence for the importance of the deregulation of the PI3K-AKT pathway in ALCL.
    Leukemia and Lymphoma 11/2005; 46(10):1463-70. · 2.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Our objective was to determine whether oral etoposide and cisplatin combination (EoP) is superior to paclitaxel in the treatment of advanced breast cancer (ABC) patients pretreated with anthracyclines. From December 1997 to August 2003, 201 patients were randomised, 100 to EoP and 101 to paclitaxel arms. Four patients in each arm were ineligible. The doses of etoposide and cisplatin were 50 mg p.o. twice a day for 7 days and 70 mg m(-2) intravenously (i.v.) on day 1, respectively, and it was 175 mg m(-2) on day 1 for paclitaxel. Both treatments were repeated every 3 weeks. A median of four cycles of study treatment was given in both arms. The response rate obtained in the EoP arm was significantly higher (36.3 vs 22.2%; P=0.038). Median response duration was longer for the EoP arm (7 vs 4 months) (P=0.132). Also, time to progression was significantly in favour of the EoP arm (5.5 vs 3.9 months; P=0.003). Median overall survival was again significantly longer in the EoP arm (14 vs 9.5 months; P=0.039). Toxicity profile of both groups was similar. Two patients in each arm were lost due to febrile neutropenia. The observed activity and acceptable toxicity of EoP endorses the employment of this combination in the treatment of ABC following anthracyclines.
    British Journal of Cancer 03/2005; 92(4):639-44. · 5.08 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The vagina as a primary site of malignant lymphoma in woman is extremely rare. We report here a 30-year-old patient with a primary vaginal non-Hodgkin's lymphoma stage IEA, follicular large cell of B lineage, with an excellent response to cytotoxic chemotherapy (CHOP) and event-free survival of 28 months. Primary involvement of the vagina can be successfully treated by pelvic irradiation, but in young women chemotherapy should be considered to preserve fertility, as well as quality of life.
    Archives of Gynecology and Obstetrics 04/2004; 269(3):208-10. · 1.33 Impact Factor
  • Emin Kansu, Aysegül Uner, James R McArthur
    Hematology 03/2004; 9(1):79-80. · 1.39 Impact Factor
  • James R McArthur, Emin Kansu, Aysegül Uner
    Hematology 09/2003; 8(4):273-4. · 1.39 Impact Factor
  • James R McArthur, Emin Kansu, Aysegül Uner
    Hematology 05/2003; 8(2):125-7. · 1.39 Impact Factor
  • James R McArthur, Emin Kansu, Aysegül Uner
    Hematology 03/2003; 8(1):61-3. · 1.39 Impact Factor
  • James R McArthtur, Emin Kansu, Aysegül Uner
    Hematology 11/2002; 7(5):311-3. · 1.39 Impact Factor
  • James R McArthtur, Emin Kansu, Aysegül Uner
    Hematology 09/2002; 7(4):263-4. · 1.39 Impact Factor
  • James R McArthtur, Emin Kansu, Aysegül Uner
    Hematology 07/2002; 7(3):201-2. · 1.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: CD44 variant exon 6 (v6) belongs to a family of transmembrane glycoproteins involved in cell adhesion. To determine the prognostic role of CD44v6 in laryngeal cancer and to examine its relation with other clinicopathologic prognostic factors. A retrospective cohort study was designed with 93 laryngeal cancer cases. They were selected randomly from patients treated with laryngectomy between January 1, 1983, and December 31, 1993. Faculty of Medicine, Hacettepe University, Ankara, Turkey. The ages of the patients ranged from 31 to 73 years. Eighty-eight patients were men and 5 were women. Three had stage I, 33 had stage II, 27 had stage III, and 30 had stage IV disease at the time of surgery. Histological sections of tumors and metastatic lymph nodes were reevaluated for several histopathological factors. Sections were stained using anti-CD44v6 monoclonal antibody by immunohistochemical methods. CD44v6 expression was seen only in the lower one third of the normal squamous epithelium but in all layers of dysplasia and in situ carcinoma. Besides a general evaluation of tumor staining, immunostaining was evaluated separately for cell groups located in the center of neoplastic islands (nonbasal cells), at the periphery of the neoplastic islands (basal cells), and at the infiltration zones (marginal cells). Decreased disease-free survival was noted when there was extensive staining in the general evaluation and in cases with extensive staining in marginal and nonbasal cells (P =.03). Using Cox regression analysis, the greatest dimension of the largest metastatic lymph node and extensive expression of CD44v6 in nonbasal tumor cells were independent prognostic factors. Our results suggest that CD44v6 expression is an important prognostic factor in laryngeal cancer.
    Archives of Otolaryngology - Head and Neck Surgery 05/2002; 128(4):393-7. · 1.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Four cycles of AC have been accepted as the standard chemotherapy in breast cancer. In the present randomized study we aimed to assess the efficacy of adjuvant etoposide + cisplatin (EP) combination following four cycles of standard adriamycin + cyclophosphamide (AC) in premenopausal patients with operable breast cancer and axillary lymph node metastasis. Premenopausal patients with positive axillary lymph nodes following curative modified radical mastectomy were randomized to either four cycles of AC (82 patients) or four cycles of AC + two cycles of EP (83 patients). Median follow-up is 72 months. All randomized and eligible patients are included in the analysis (AC: 80 patients, AC + EP: 78 patients). The five-year disease-free survival (DFS) for the AC + EP group was significantly better when compared to AC group (45.5% vs. 30.4%; P = 0.048). Again, the five-year overall survival (OS) of the whole group was in favor of AC + EP arm, though without statistical significance (68.6% vs. 59.1%; P = 0.247). Two cycles of EP following four cycles of AC decreased the relapse rate in operable breast cancer patients.
    Annals of Oncology 08/2001; 12(7):1011-3. · 7.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The differential diagnosis of eosinophilia may sometimes be difficult. Eosinophilia may occur in a diverse array of conditions from parasitic infestations to malignacies. Idiopathic hypereosinophilic syndrome has also been described. A 65-year-old male patient presenting with eosinophilia of obscure etiology is described in the present report. Three years after the diagnosis of eosinophilia, metastatic anaplastic carcinoma of unknown primary was detected. Differential diagnosis is disscussed briefly. It is stressed that patients with hypereosinophilia of unknown etiology must be screened for malignancy regularly during follow up.
    Medical Oncology 02/2001; 18(4):285-8. · 2.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary central nervous system lymphomas (PCNSL) represent only 1% of all non-Hodgkin's lymphomas (NHLs). A 66 year-old woman was hospitalized due to multiple episodes of syncope and seizures which occurred the week before admission to the hospital. A computerized tomography (CT) scan of the brain showed a right parietal lesion suggesting a subdural effusion. The patient was operated and a dural lesion extending to the epidural space and cerebral cortex was excised. Histologic findings suggested diagnosis of a low-grade lymphoma of the mucosa associated lymphoid tissue (MALT) type. The patient was treated with radiation therapy and has now completely recovered 12 months after surgery.
    Journal of experimental & clinical cancer research: CR 07/2000; 19(2):249-51. · 1.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Our objective was to assess the efficacy of a standard dose ifosfamide and doxorubicin containing regimen in the treatment of advanced soft tissue sarcomas. Forty consecutive patients with a median age of 35.5 years were treated. Ifosfamide was administered at a dose of 2.5 g/m(2)/day as 72-hour continuous infusion with mesna at the same dosage and schedule. Doxorubicin was given at the dose of 60 mg/m(2)/day as 2-hour infusion on day 1. Six patients had a complete response (15%), and 9 (22.5%) had a partial response, fourteen patients (35%) stable disease, and 11 (27.5%) did not respond to chemotherapy. The median duration of response was 13 and 5 months for the complete and partial responders, respectively. The median survival was 37 months. Febrile neutropenia was encountered in 9 cases (22.5%). The present ifosfamide and doxorubicin combination is a moderately effective and well-tolerable regimen in the treatment of advanced soft tissue sarcomas.
    Journal of Surgical Oncology 02/2000; 73(1):12-6. · 2.64 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Gastric carcinoma is a substantial health problem in Turkey, and the majority of patients present with inoperable disease. The aim of this randomized trial was to assess the activity of 5-fluorouracil versus etoposide when combined with epirubicin plus cisplatin in patients with advanced gastric carcinoma (AGC). In this prospective, randomized, multicenter Phase III study, previously untreated patients with histopathologically proven AGC enrolled after giving informed consent. Patients were allocated to receive either EEP (etoposide 120 mg/m2, epirubicin 30 mg/m2, and cisplatin 40 mg/m2 on Days 1 and 8) or FEP (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, and cisplatin 80 mg/m2 on Day 1), and the regimens were to be repeated every fourth week. Of a total of 131 eligible patients, 64 were in the EEP group and 67 were in the FEP group. The objective response (complete + partial) rates for evaluable patients (n = 118) were comparable (P = 0.63) in the EEP (20.3%, 12/59) and FEP (15.3%, 9/59) groups, respectively. Actuarial analyses revealed comparable median progression free survival (6 vs. 7 months, P > 0.05) and overall survival (6 vs. 5 months, P > 0.05) duration in the EEP and FEP groups. Both regimens were well tolerated. The most common toxicity was Grade 1-2 nausea with or without vomiting. No chemotherapy-related death occurred. The current study resulted in inadequate response rates for EEP and FEP regimens. Neither combination, as used at the doses and schedules in this study, can be recommended as standard treatment for patients with AGC.
    Cancer 12/1998; 83(12):2475-80. · 5.20 Impact Factor

Publication Stats

145 Citations
56.79 Total Impact Points


  • 2000–2005
    • Hacettepe University
      • • Institute of Oncology
      • • Department of Medical Oncology
      Ankara, Ankara, Turkey
  • 2002–2003
    • University of Washington Seattle
      Seattle, Washington, United States
  • 1993
    • Ibn Sina Hospital Dhanmondi
      Baghdād, Mayorality of Baghdad, Iraq
    • Ankara University
      • Department of Medical Oncology
      Engüri, Ankara, Turkey